Pomerantz Law Firm Investigates Boston Scientific Following Q3 Earnings Miss and Guidance Downgrade
Pomerantz LLP has launched an investigation into Boston Scientific Corporation (BSX) following the company's disappointing third-quarter 2026 financial results. The investigation seeks to determine if the company or its executives engaged in securities fraud or unlawful business practices related to recent disclosures. The scrutiny follows a Q3 earnings miss and the third consecutive quarter of lowered sales and earnings guidance. Management cited significant operational fallout from a major cybersecurity incident, as well as structural challenges within the Watchman heart device and electrophysiology segments, as primary drivers for the downward revisions.
Tickers: $BSX
Topics: class action lawsuit cybersecurity incident earnings miss guidance downgrade securities fraud investigation